600276.SS · 恒瑞医药
China A-shares · RS rating 25 · As of 2026-10-14
| Price | 45.49 CNY |
|---|---|
| 1-day change | -0.0% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 70 / 23 / 17 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 20 / 19 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -10.1% |
| Distance from 52-week high | +37.1% |
| Market cap (USD) | $46.7B |